John A. Herrmann III - 28 May 2021 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
EVP, Chief Legal Officer
Signature
/s/ John A. Herrmann III
Issuer symbol
NVAX
Transactions as of
28 May 2021
Net transactions value
-$388,815
Form type
4
Filing time
02 Jun 2021, 16:59:38 UTC
Next filing
29 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise $11,482 +416 +151% $27.60 691 28 May 2021 Direct F1
transaction NVAX Common Stock Options Exercise $19,182 +417 +60% $46.00* 1,108 28 May 2021 Direct F1
transaction NVAX Common Stock Options Exercise $12,269 +2,062 +186% $5.95 3,170 28 May 2021 Direct F1
transaction NVAX Common Stock Sale $127,739 -864 -27% $147.85* 2,306 28 May 2021 Direct F1, F2
transaction NVAX Common Stock Sale $165,105 -1,109 -48% $148.88* 1,197 28 May 2021 Direct F1, F3
transaction NVAX Common Stock Sale $77,452 -517 -43% $149.81* 680 28 May 2021 Direct F1, F4
transaction NVAX Common Stock Sale $36,258 -240 -35% $151.08* 440 28 May 2021 Direct F1, F5
transaction NVAX Common Stock Sale $14,450 -95 -22% $152.11* 345 28 May 2021 Direct F1, F6
transaction NVAX Common Stock Sale $10,744 -70 -20% $153.49* 275 28 May 2021 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 +416 +17% $0.000000 2,928 28 May 2021 Common Stock 416 $27.60 Direct F1, F8
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 +417 +5.6% $0.000000 7,926 28 May 2021 Common Stock 417 $46.00 Direct F1, F9
transaction NVAX Stock Option (Right to Buy) Options Exercise $0 +2,062 +3.7% $0.000000 57,751 28 May 2021 Common Stock 2,062 $5.95 Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.42 to $148.40, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F3 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.45 to $149.41, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F4 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.47 to $150.40, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F5 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.68 to $151.67, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F6 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.78 to $152.56, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F7 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.43 to $153.82, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F8 Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
F9 Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
F10 Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.